Merck KGaA

To challenge Ocrevus, German Merck takes on Aubagio
To challenge Ocrevus, German Merck takes on Aubagio
EP Vantage
Ocrevus
Merck KGaA
Aubagio
evobrutinib
MS
multiple sclerosis
Flag link:
Merck KGaA selling manufacturing site, allergy drugs to Dermapharm
Merck KGaA selling manufacturing site, allergy drugs to Dermapharm
Fierce Pharma
Merck KGaA
Dermapharm
drug manufacturing
Flag link:
Allergan, Merck KGaA and Sai Life Sciences Invest in New Global Manufacturing Facilities
Allergan, Merck KGaA and Sai Life Sciences Invest in New Global Manufacturing Facilities
BioSpace
Allergan
Merck KGaA
Sai Life Sciences
drug manufacturing
Flag link:
Merck KGaA spinout iOnctura raises cash for cancer trials
Merck KGaA spinout iOnctura raises cash for cancer trials
Fierce Biotech
Merck KGaA
iOnctura
clinical trials
IOA-244
cancer
solid tumors
Flag link:
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Endpoints
Merck KGaA
Pfizer
Bavencio
bladder cancer
FDA
Flag link:
Corporate and regulatory developments over the Christmas period
Corporate and regulatory developments over the Christmas period
EP Vantage
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Flag link:
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
Flag link:
Merck KGaA posts higher profit and revenue as it lifts sales forecast
Merck KGaA posts higher profit and revenue as it lifts sales forecast
Marketwatch
Merck KGaA
earnings
Flag link:
Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial
Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial
Marketwatch
Merck KGaA
Pfizer
Bavencio
clinical trials
gastric cancer
Flag link:
Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there
Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there
Endpoints
Merck KGaA
China
innovation
Shanghai
Flag link:
Merck and the machine: German pharma tests real-time platform to forestall drug shortages
Merck and the machine: German pharma tests real-time platform to forestall drug shortages
Fierce Pharma
Merck KGaA
drug shortages
machine learnings
artificial intelligence
Flag link:
Merck seeks partner for disease-modifying osteoarthritis drug
Merck seeks partner for disease-modifying osteoarthritis drug
PM Live
Merck KGaA
osteoporosis
sprifermin
Flag link:
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug
Pharmaforum
FDA
Merck KGaA
MET
lung cancer
tepotinib
non-small cell lung cancer
Flag link:
Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma
Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma
Endpoints
GSK
oncology
Merck KGaA
Maya Martinez-Davis
Flag link:
Tackling the remaining challenges of multiple sclerosis
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Merck KGaA
MS
multiple sclerosis
evobrutinib
Flag link:
Startup offering free DNA sequencing signs first pharma sponsor
Startup offering free DNA sequencing signs first pharma sponsor
Stat
Nebula Genomics
DNA sequencing
EMD Serono
Merck KGaA
Flag link:
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Pharmaforum
Merck KGaA
Pfizer
Bavencio
FDA
Inlyta
advanced renal cell carcinoma
Flag link:
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Fierce Biotech
Merck KGaA
bispecific antibodies
f-star
drug discovery
Flag link:
German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
FDA
Merck KGaA
cladribine
MA
multiple sclerosis
Flag link:

Pages